Novavax (NVAX) announced a milestone payment from Takeda (TAK) has been triggered by regulatory approval for Novavax’s COVID-19 vaccine Nuvaxovid Intramuscular Injection 1 mL formulated to target SARS-CoV-2 Omicron LP.8.1 as an initial immunization (first and second vaccination) for those aged six years or older and a booster immunization (after the third vaccination) for those aged 12 years or older. Novavax is eligible to receive royalties on net sales of Nuvaxovid from Takeda this vaccination season. A portion of the milestone payment can be credited towards future royalty payments. These payments are part of the updated and significantly improved terms of Novavax’s collaboration and licensing agreement with Takeda, announced earlier this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- FDA vaccine chief overruled scientists on Covid shot access, NY Times reports
- Novavax ‘applauds’ President Trump’s call for available COVID-19 vaccine data
- Florida surgeon general says state will eliminate vaccine mandates
- Optimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy Rating
- Kohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by Analysts